Preview
Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone approved by the United States Food and Drug Administration in December 1999. Few side effects of this new antibiotic have been reported, and there are no previous case reports of bradyarrhythmias. We report 2 cases of syncope due to bradycardia in patients who recently began treatment with gatifloxacin.
Journal Article. 1743 words. Illustrated.
Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology
Go to Oxford Journals » abstract
Full text: subscription required
How to subscribe Recommend to my Librarian
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.